Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Ginkgo Bioworks Holdings, Inc.

Grow by Ginkgo

At Ginkgo, we use biology to grow the future. Companies across industries leverage our platform to design, develop, and optimize products for a breadth of commercial applications. We help our partners grow key ingredients for vaccines, crops that rely less on fossil fuel-based fertilizers, plant-based meat that tastes like the real thing, materials for the next generation of circular fashion, and so much more. We know our unique experiences, ideas, and perspectives are essential to our success and enable us to make biology easier to engineer and ensure equitable distribution of the benefits of our platform. As such, we seek to ensure that DEI is in our DNA, continuing to grow an inclusive culture and diverse workforce. Let's make biology easier to engineer and join our team.

Synlogic

Empede Capital

General Atlantic

Y Combinator

Bill Gates

Cascade Investment

T. Rowe Price

Viking Global Investors

Illumina

Ginkgo Bioworks, Inc.

Today on Foundry Theory we're all about iGEM - the heart of synthetic biology.
https://hubs.la/Q02kdx3q0

Humans of Ginkgo Bioworks is an interview series, featuring Sudeep Agarwala, that dives into the exciting technology at Ginkgo.

Today, we've released the final part of our three-part interview with Ginkgo’s head of ALE, Simon Trancart!

In Part 3, Simon discusses how our partners are working with us to make automated ALE at Ginkgo accessible to new industries.

Read it here:
https://hubs.la/Q02k9M_00

Catch up on Part 1 here: https://hubs.la/Q02k9Pbj0

And Part 2 here: https://hubs.la/Q02k9M8z0

Thank you, Elaine Watson and AgFunder, for the great featuring of our offering and strategic collaborations with Ginkgo Bioworks, Inc. and dsm-firmenich toward launching our products.

Tal Zeltzer | Sandro Tomita | Fredrik Hjelmqvist | David Borhani | Kevin Madden

#DOD Biomanufacturing RFP is out 👇🏻👇🏻 

https://lnkd.in/e6Bk8jtW

When I started my NSC detail, I knew very little about #biomanufacturing but after drinking from a firehose on the topic for a few months I came to see the plethora of ways this growing ecosystem of bio companies and technologies can strengthen America; from improving sustainability, strengthening supply chains, and growing the economy.

This RFP is an opportunity to invest in building Biomanufacturing capacity across the country. It's great to see it posted.

Congrats to all the people who worked hard to get this done: Kate Sixt Peter Emanuel Michelle Rozo Kirsten Kulcsar Weand, PhD Anne Cheever Georgia Lagoudas Sarah Glaven Douglas Friedman Robert Fisher Ben Buchanan Ishan K. Sharma and many others.

Check out Nita Madhav and friends as they figure out how to ensure we don't have another major biological event in our lifetimes. https://lnkd.in/eN94t7_F

Die Teilnehmer*innen der Delegationsreise in die USA hatte die Gelegenheit, Ginkgo Bioworks, Inc. zu besuchen und einen Einblick in deren Entwicklung und Labors zu erhalten.

Ginkgo Bioworks ist ein Biotech-Unternehmen, das sich auf die gentechnische Herstellung von Bakterien für industrielle Anwendungen spezialisiert hat. Die Expertise des Unternehmens erstreckt sich über die Entwicklungen von Mikroorganismen bis hin zur Herstellung von synthetischen Zellen, die schließlich die Grundlage für die Produktion verschiedener Materialien bilden können.

Der Besuch ermöglichte es neueste Fortschritte und Innovationen im Bereich der Genomtechnologie zu erkunden. Die Labors boten Einblicke in die Präzisionsarbeit, die hinter der Entwicklung maßgeschneiderter Mikroorganismen steht. Philipp Heuermann zeigten die internationalen Perspektiven von Ginkgo Bioworks auf.

VDMA, Wittenstein Stiftung, Universität Hohenheim, Universität Stuttgart, Baden-Württemberg International (BW_i), Thomas Bauernhansl

This is biology's century.

Just as computer science transformed the 20th century, biological science will transform the 21st. 

Alison Snyder explores growing global competition to harness that science to develop and make biotechnology products at scale.

More in In Axios Science👇🏾 

https://lnkd.in/eakijuky

“Biology is the only substrate, the only scientific discipline, that is capable of solving the great challenges of the world—food security, climate change, human health—all of those are biological problems”🦠🧬🧫🌱🍄🐝

Enjoyed chatting with Mark Sullivan at Forbes about the intersection of AI and Biology. 

https://lnkd.in/eZH8EZQ6

Thanks to the The Burn Bag and Andrea Ochoa for a great conversation about biology as a domain of operations, bio-intelligence (BIOINT), and the coming era of biosecurity.

Listen here: bit.ly/49muHGI

Ginkgo Bioworks, Inc.

Are your new product development efforts limited by commercially available enzyme technology? What if you could discover or design the exact enzyme needed to unlock your next innovation? See how one of our customers utilized Ginkgo's scale, automation, and AI algorithms to discover their unique enzyme. 

Interested? Contact us here to learn more! https://hubs.la/Q02jV4hY0

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
net income	-119.86M -	-126.72M 5.73%	-1.84B 1,349.34%	-2.11B 14.69%	-892.87M 57.61%
depreciation and amortization	10.76M -	13.86M 28.91%	29.08M 109.72%	44.42M 52.78%	71.55M 61.07%
deferred income tax	54.73M -	4.13M 92.46%	30.21M 631.70%	-14.61M 148.35%	-801K 94.52%
stock based compensation	771K -	476K 38.26%	1.61B 337,299.16%	1.93B 20.21%	229.88M 88.09%
change in working capital	10.58M -	-26.52M 350.69%	-61.54M 132.08%	-37.01M 39.86%	29.84M 180.63%
accounts receivables	-1.84M -	-14.23M 672.00%	-114.09M 701.90%	55.02M 148.23%	50.07M 9.01%
inventory	-2.22M -	-2.74M 23.13%	-626K 77.12%	164K 126.20%
accounts payables	664K -	7.02M 957.08%	-2.25M 132.01%	-10.84M 382.60%	-1.18M 89.09%
other working capital	13.98M -	-16.57M 218.54%	55.43M 434.52%	-81.35M 246.76%	-19.05M 76.59%
other non cash items	-1.64M -	-1.06M 35.38%	-20.95M 1,874.27%	-69.28M 230.72%	266.89M 485.27%
net cash provided by operating activities	-44.66M -	-135.83M 204.12%	-253.82M 86.86%	-252.20M 0.64%	-295.50M 17.17%
investments in property plant and equipment	-22.22M -	-57.82M 160.23%	-56.52M 2.25%	-52.27M 7.52%	-40.80M 21.94%
acquisitions net			-12.04M -	26.65M 321.31%	-38.55M 244.68%
purchases of investments	-50.13M -		-5M -	-3.69M 26.18%
sales maturities of investments
other investing activites	-2.25M -	-9.30M 313.33%	304K 103.27%	-38.08M 12,625.66%	-1.34M 96.48%
net cash used for investing activites	-74.60M -	-67.12M 10.03%	-73.26M 9.14%	-67.39M 8.00%	-80.69M 19.73%
debt repayment	-828K -	-748K 9.66%	-1.12M 50.13%	-1.24M 10.15%	-1.29M 4.69%
common stock issued		91.07M -	1.51B 1,557.91%	99.30M 93.42%	-487K 100.49%
common stock repurchased	-408K -		-25.00M -	-981K 96.08%
dividends paid			-1.51B -	-981K 99.94%
other financing activites	411.62M -	90.32M 78.06%	1.56B 1,627.52%	-767K 100.05%	-1.43M 86.96%
net cash used provided by financing activities	410.38M -	90.32M 77.99%	1.53B 1,598.60%	95.34M 93.79%	-3.22M 103.37%
effect of forex changes on cash			-19K -	908K 4,878.95%	-588K 164.76%
net change in cash	291.12M -	-112.63M 138.69%	1.21B 1,171.67%	-223.35M 118.50%	-375.15M 67.97%
cash at beginning of period	207.39M -	498.51M 140.37%	385.88M 22.59%	1.59B 312.81%	1.32B 16.88%
cash at end of period	498.51M -	385.88M 22.59%	1.59B 312.81%	1.37B 14.02%	948.86M 30.72%
operating cash flow	-44.66M -	-135.83M 204.12%	-253.82M 86.86%	-252.20M 0.64%	-295.50M 17.17%
capital expenditure	-22.22M -	-57.82M 160.23%	-56.52M 2.25%	-52.27M 7.52%	-40.80M 21.94%
free cash flow	-66.88M -	-193.65M 189.54%	-310.34M 60.26%	-304.47M 1.89%	-336.30M 10.45%

NYSE:DNA

Ginkgo Bioworks Holdings, Inc.

Last Close

0.84

17/05 20:00

Market Cap

2.73B

Beta: 0.89

Volume Today

31.31M

Avg: 18.92M

PE Ratio

−2.78

PFCF: −6.38